Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

NCT03980171 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Venetoclax
DRUG: Lenalidomide

Sponsor

Peter MacCallum Cancer Centre, Australia